<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306887</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3101-II-02</org_study_id>
    <nct_id>NCT04306887</nct_id>
  </id_info>
  <brief_title>A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)</brief_title>
  <official_title>A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 in Subjects With Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with
      relapsed/refractory anaplastic large cell lymphoma (ALCL) .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Baseline up to 18 months</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) according to Lugano response criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) within 2-year</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) within 2-year</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>OS was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)</condition>
  <arm_group>
    <arm_group_label>TQ-B3101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3101 capsule administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3101 capsule</intervention_name>
    <description>Escalating doses starting at 200 mg bid.</description>
    <arm_group_label>TQ-B3101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1.Female or male, 10 years and older. 2.Eastern Cooperative Oncology Group (ECOG)
        performance status score of 0 to 2. 3.Histologically or cytologically confirmed ALK
        positive relapsed or refractory Anaplastic Large Cell Lymphoma.

        4.At least one measurable lesion. 5.Life expectancy ≥ 3 months. 6.Adequate organ system
        function. 7.Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1.Primary cutaneous anaplastic large cell lymphoma. 2.Other malignancies occurred
             within 5 years, with exception of cured cervical carcinoma in situ, non-melanoma skin
             cancer, and superficial bladder tumors.

             3.Has received ALK inhibitor. 4.Has received an allogeneic stem cell transplant. 5.Has
             received autologous stem cell transplant within 12 weeks before the first
             administration.

             6.Has received other anti-tumor medications within 4 weeks of the first
             administration.

             7.Has received major surgery within 4 weeks before the first administration. 8.Has
             received any curative radiotherapy or minor surgery within 2 weeks before the first
             administration.

             9.Has received palliative radiation therapy within 2 days before the first
             administration.

             10.Has adverse events caused by previous therapy except alopecia that did not recover
             to ≤grade 1.

             11.Has uncontrollable congestive heart failure. 12.According to the judgement of the
             researchers, there are other factors that subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huiqiang Huang</last_name>
    <phone>020-87343349</phone>
    <email>huanghq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiqiang Huang</last_name>
      <phone>020-87343349</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Huiqiang Huang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

